News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Topigen Pharmaceuticals Inc. To Present At Two Upcoming Medical Conferences


9/29/2008 12:17:16 PM

Montreal, Canada, September 25, 2008 -- TOPIGEN Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, today announced that the company will speak at two leading medical conferences in October; The European Respiratory Society (ERS) 18th Annual Congress and The Oligonucleotide Therapeutics Society (OTS) 4th Annual Meeting. The Company will provide information on its two lead clinical product candidates, TPI ASM8 for asthma and TPI 1020 for COPD, both currently in Phase II studies, as well as its Phase I product candidate, TPI 1100 for COPD.

TOPIGEN Pharmaceuticals will make two presentations at The European Respiratory Society (ERS) 18th Annual Congress, which takes place on October 4-8, 2008 in Berlin, Germany. For more information on the conference, please visit http://dev.ersnet.org/

First Presentation Information at ERS:

Title: "Safety, Efficacy and Pharmacokinetics of Inhaled TPI 1020 in Smokers with Asthma" Who: Louis-Philippe Boulet (Principle Investigator), Hopital Laval, Quebec City Where: Messe Berlin GmbH, Room 5.2a When: Tuesday, October 7 at 8:30 A.M. Second Presentation Information at ERS:

Title: "Advantageous Toxicity Profile of Novel Inhaled Antisense Oligonucleotides, TPI ASM8 and TPI 1100, Following Chronic Dosing in Monkeys." Who: Nicolay Ferrari, Ph.D., Director, Pharmacology, TOPIGEN Pharmaceuticals Inc. Where: Messe Berlin GmbH, Europa 2 room When: Tuesday, October 7 at 4:00 P.M.

TOPIGEN Pharmaceuticals will also present at The Oligonucleotide Therapeutics Society (OTS) 4th Annual Meeting, which takes place on October 15-18, 2008 in Boston, MA. For more information on the conference, please visit http://www.myots.org/

Presentation Information at OTS:

Title: "TPI 1100: A Novel Inhaled FANA-containing Antisense Oligonucleotide Product Against Phosphodiesterase 4 and 7 for the Treatment of COPD" Who: Nicolay Ferrari, Ph.D., Director, Pharmacology, TOPIGEN Pharmaceuticals Inc. Where: Harvard Medical School Conference Center in Boston, MA When: Friday, October 17 at 4:40 - 5:05 P.M.

About TOPIGEN

TOPIGEN is a privately held, clinical-stage company focused on developing new classes of inhaled drugs for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. TOPIGEN is actively progressing two drug candidates in Phase II trials for COPD and asthma, including TPI 1020, a novel small molecule anti-inflammatory and TPI ASM8, based on the company's proprietary mRNA-silencing technology. These drug candidates target multiple pathways and pro-inflammatory mediators involved in chronic inflammatory pulmonary diseases.

Current venture investors include NovaQuest, MMV Financial, Inc., BDC Venture Capital, Fonds de solidarite FTQ, Desjardins Venture Capital, Caisse de dépot et placement du Québec (Caisse), T2C2/BIO 2000 and Lothian Partners 27 (sarl) SICAR. For more detailed information on TOPIGEN visit www.topigen.com.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES